Gaia Giannone (@gaia_giannone) 's Twitter Profile
Gaia Giannone

@gaia_giannone

Medical oncologist, clinical research fellow @imperialcollege 🇮🇹 🇬🇧
#GyneOnco #research #genomics

ID: 1199208999633244162

calendar_today26-11-2019 06:11:43

84 Tweet

268 Takipçi

365 Takip Edilen

Gaia Giannone (@gaia_giannone) 's Twitter Profile Photo

Vi aspettiamo oggi alle 16.00 CET per un nuovo imperdibile appuntamento dei MITICI Lunedì 🎯🧬#ovariancancer #MITOgroup #JC

Vi aspettiamo oggi alle 16.00 CET per un nuovo imperdibile appuntamento dei MITICI Lunedì 🎯🧬#ovariancancer #MITOgroup #JC
Gaia Giannone (@gaia_giannone) 's Twitter Profile Photo

You don't want to miss this 👇 Join us virtually on Feb 13th, 14.00 CET to discover the power of AI in pathology Jakob Nikolas Kather @chiaralöffler Sandro pignata #miticilunedì #MITO #gynaeonc

You don't want to miss this 👇
Join us virtually on Feb 13th, 14.00 CET to discover the power of AI in pathology <a href="/jnkath/">Jakob Nikolas Kather</a> @chiaralöffler <a href="/PignataSandro/">Sandro pignata</a> #miticilunedì #MITO #gynaeonc
Ovarian Cancer Action (@ovariancanceruk) 's Twitter Profile Photo

Today is #InternationalDayOfWomenAndGirlsInScience and here are just a few of the incredible women we have the privilege of working with. Each of these scientists is working relentlessly to make breakthroughs that will save the lives of women with #OvarianCancer. 👏

Today is #InternationalDayOfWomenAndGirlsInScience and here are just a few of the incredible women we have the privilege of working with. Each of these scientists is working relentlessly to make breakthroughs that will save the lives of women with #OvarianCancer. 👏
Gruppo MITO (@gruppomito) 's Twitter Profile Photo

È stato pubblicato lo studio MITO-END3 su The Lancet Oncology che ha valutato l’aggiunta dell’immunoterapia (avelumab) alla chemioterapia nel setting del carcinoma dell’endometrio in stadio avanzato/ricorrente bit.ly/3jS979a #endometrialcancer #immunotherapy #oncology

È stato pubblicato lo studio MITO-END3 su The Lancet Oncology che ha valutato l’aggiunta dell’immunoterapia (avelumab) alla chemioterapia nel setting del carcinoma dell’endometrio in stadio avanzato/ricorrente

bit.ly/3jS979a

#endometrialcancer #immunotherapy #oncology
Gaia Giannone (@gaia_giannone) 's Twitter Profile Photo

Such an unforgettable weekend in Palermo for AIOM #2023 CANCER RESEARCH: great talks, stunning location and the best company you could ask for!

Such an unforgettable weekend in Palermo for <a href="/AIOMtweet/">AIOM</a> #2023 CANCER RESEARCH: great talks, stunning location and the best company you could ask for!
ESMO - Eur. Oncology (@myesmo) 's Twitter Profile Photo

ESMO has announced the names of the 2023 fellowship awardees who will be celebrated during the YO Fellowship session at #ESMO23. The awardees are Pasquale Lombardi, Maximilian Mair, Gil Awada, Natalie Ngoi, and Nadia Saoudi González. 👉esmo.org/career-develop…

ESMO has announced the names of the 2023 fellowship awardees who will be celebrated during the YO Fellowship session at #ESMO23. The awardees are Pasquale Lombardi, <a href="/MJ_Mair/">Maximilian Mair</a>, Gil Awada, <a href="/NatalieNgoi/">Natalie Ngoi</a>, and <a href="/nadiasago/">Nadia Saoudi González</a>.
👉esmo.org/career-develop…
ESMO - Eur. Oncology (@myesmo) 's Twitter Profile Photo

ESMO congratulates the recipients of the 2023 Research Fellowships & the José Baselga Fellowship, celebrated today at the YO Fellowship session at #ESMO23. 👏 Gil Awada, Pasquale Lombardi, Maximilian Mair, Natalie Ngoi and Nadia Saoudi González, Myriam Chalabi 👉ow.ly/wZyL50PZqnC

ESMO congratulates the recipients of the 2023 Research Fellowships &amp; the José Baselga Fellowship, celebrated today at the YO Fellowship session at #ESMO23.  
👏 Gil Awada, Pasquale Lombardi, <a href="/MJ_Mair/">Maximilian Mair</a>, <a href="/NatalieNgoi/">Natalie Ngoi</a> and <a href="/nadiasago/">Nadia Saoudi González</a>, <a href="/MyriamChalabi/">Myriam Chalabi</a>
👉ow.ly/wZyL50PZqnC
OCA Research Centre (@ocarc_imperial) 's Twitter Profile Photo

Today meet Gaia who is studying complex genomic profile of high-grade serous carcinomas. Her aim is to understand which alterations in cancer cells cause their clinical behaviour and their response and resistance to new targeted drugs for a more personalized approach for patients

Today meet Gaia who is studying complex genomic profile of high-grade serous carcinomas. Her aim is to understand which alterations in cancer cells cause their clinical behaviour and their response and resistance to new targeted drugs for a more personalized approach for patients